Answers are grounded in this paper and cite their sources.
Background British Columbia, Canada introduced clinical guidance to support the prescription of pharmaceutical alternatives to the toxic unregulated drug supply in 2020, also known as prescribed safer supply (PSS). This provincial prospective cohort study evaluates the associations between PSS receipt and self-reported health and social outcomes. Methods Data were collected in 2020–2021 using a longitudinal survey of people who had received a prescription or were seeking one (n = 161), with up to 5 time points per participant over 3 months. Generalised estimating equations were used to assess the effects of time-varying prescription exposure (yes/no) on outcomes over the follow-up period, controlling for encounters with police and bylaw officers, service use, social support, and sociodemographic characteristics. Outcomes included quality of life (EuroQOL-5D), depression (PHQ-2), anxiety (GAD-2), frequency of unregulated substance use, COVID-19 protective behaviours, and reliance on criminalized income sources. Results PSS receipt was negatively associated with depression (adj. b = -0.44, 95% CI= -0.81, -0.08) and frequency of unregulated substance use (adj. b = -0.23, 95% CI = -0.45, -0.014) over the study period. Independent of PSS receipt, there was no evidence of change in outcomes over the 12 weeks, except for a small increase in COVID-19 protective behaviours over time (adj. b = 0.004, 95% CI = 0.001, 0.007). Discussion Findings signal the potential promise of PSS, along with the need for improvement of existing service models. Further research is needed to inform the development of models that combine prescriptions with comprehensive services and supports to maximize positive outcomes.
No takes yet. Share an insight, caveat, or question.
Urbanoski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: